Prostate Cancer Update

Featuring an interview with Dr Rana R McKay, including the following topics: Prostate Cancer Working Group (PCWG4) revised terminology (0:00) Cardiovascular effects associated with GnRH agonists versus antagonists; mechanism of action (2:17) Combination therapy using relugolix; factors affecting persistence and adherence to GnRH agents (12:06) Takeaways from the Phase III EMBARK study (19:36) Use...

Featuring perspectives from Dr Alexandra Drakaki, Ms Krisztina Emodi, Dr Terence Friedlander and Ms Margarita Huober, moderated by Dr Friedlander, including the following topics: Introduction: Basic Biology of Nonmetastatic Urothelial Bladder Cancer (UBC) (0:00) Systemic Therapy for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer (MIBC) (13:35) Evolving Approach to Systemic Therapy...

Featuring perspectives from Dr Ashish M Kamat and Prof Thomas Powles, including the following topics: Introduction: Life After Radical Cystectomy (0:00) Muscle-Invasive Bladder Cancer — Prof Powles (9:15) Non-Muscle-Invasive Bladder Cancer — Dr Kamat (37:49) CME information and select publications

Featuring perspectives from Dr Neeraj Agarwal and Dr Alan H Bryce, including the following topics: Introduction (0:00) Optimizing the Role of Hormonal Therapy in the Care of Patients with Prostate Cancer — Dr Bryce (2:41) Other Available and Emerging Therapeutic Approaches — Dr Agarwal (35:16) CME information and select publications

Featuring perspectives from Dr Terence Friedlander and Dr Daniel P Petrylak, including the following topics: Introduction (0:00) Role of Immunotherapeutic Strategies in the Management of Nonmetastatic Urothelial Bladder Cancer (UBC); Emerging Utility of Circulating Tumor DNA Evaluation — Dr Friedlander (3:53) Other Novel Agents and Strategies for Nonmetastatic and Metastatic UBC — Dr Petrylak (26:...

Featuring perspectives from Dr Neeraj Agarwal, Dr Elisabeth I Heath, Dr Daniel P Petrylak, Dr Fred Saad and Dr Neal D Shore, moderated by Dr Heath, including the following topics: Introduction (0:00) Evolving Management of Nonmetastatic Hormone-Sensitive Prostate Cancer (HSPC) — Dr Shore (2:12) Current Hormonal Treatment for Metastatic HSPC (mHSPC) — Dr Petrylak (27:54) Current and Future Role of...

Dr Thomas Hutson from the Sarah Cannon Research Institute in Abilene, Texas, Dr Eric A Singer from The Ohio State University Comprehensive Cancer Center in Columbus and Dr Ulka Vaishampayan from the University of Michigan Health Rogel Cancer Center in Ann Arbor discuss recent data surrounding the management of localized renal cell carcinoma and share their perspectives on the clinical application....

Professor Thomas Powles from Barts Cancer Institute in London, United Kingdom, discusses recent developments with circulating tumor DNA assays in the management of urothelial bladder cancer. CME information and select publications

Professor Thomas Powles from Barts Cancer Institute in London, United Kingdom, discusses recent developments with circulating tumor DNA assays in the management of urothelial bladder cancer. CME information and select publications here .

Dr Wassim Abida from Memorial Sloan Kettering Cancer Center in New York, New York, discusses the role of PARP inhibitors in the management of hormone-sensitive and castration-resistant metastatic prostate cancer. CME information and select publications here .

Dr Andrew J Armstrong from the Duke Cancer Institute in Durham, North Carolina, and Dr Scott T Tagawa from Weill Cornell Medicine Meyer Cancer Center in New York, New York, discuss the selection and sequencing of therapy for patients with prostate cancer and summarize major advances in the treatment landscape over the past year. CME information and select publications here .

Dr Matthew Milowsky from the UNC Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, comments on real patient cases of metastatic urothelial bladder cancer presented by Dr Jacqueline T Brown from the Emory University School of Medicine in Atlanta, Georgia, and Dr Nazli Dizman from The University of Texas MD Anderson Cancer Center in Houston. CME information and select publicatio...

Prof Karim Fizazi from the Centre Oscar Lambret in Lille, France, Dr Daniel George from the Duke Cancer Institute in Durham, North Carolina, and moderator Dr Elisabeth I Heath from Mayo Clinic in Rochester, Minnesota, discuss...

Dr Matthew Milowsky from the UNC Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, comments on real patient cases of metastatic urothelial bladder cancer presented by Dr Jacqueline T Brown from the Emory University School of Medicine in Atlanta, Georgia and Dr Nazli Dizman from The University of Texas MD Anderson Cancer Center in Houston. CME information and select publication...

Dr Matthew D Galsky from The Tisch Cancer Institute in New York, New York, Dr Shilpa Gupta from Cleveland Clinic’s Taussig Cancer Institute in Ohio, Prof Andrea Necchi from IRCCS San Raffaele Hospital in Milan, Italy, and moderator Dr Terence Friedlander from the University of California, San Francisco discuss recent data surrounding the management of non-muscle-invasive and muscle-invasive bladde...

Dr Terence Friedlander discusses the selection and sequencing of therapy for patients with bladder cancer and reviews clinical findings recently presented at the 2025 ESMO Congress. CME information and select publications here .

Dr Fern Anari from the Fox Chase Cancer Center in Philadelphia, Pennsylvania, and Dr Catherine Fahey from the Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, present real patient cases on metastatic bladder cancer, with additional commentary from Dr Matthew Galsky from The Tisch Cancer Institute in New York, New York. CME information and select publications here .

Dr McKay discusses the selection of and efficacy data with androgen pathway-targeting agents for patients with prostate cancer and reviews recently presented clinical findings from the ESMO Congress 2025. CME information and select publications here .

Dr Terence Friedlander discusses the selection and sequencing of therapy for patients with bladder cancer and reviews clinical findings recently presented at the 2025 ESMO Congress. CME information and select publications here .

Dr Rana R McKay discusses the selection and sequencing of therapy for patients with prostate cancer in a review of recently presented clinical findings from ESMO Congress 2025. CME information and select publications here .

Dr Catherine Fahey from the Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, and Dr Fern Anari from the Fox Chase Cancer Center in Philadelphia, Pennsylvania, present real patient cases on metastatic bladder cancer, with additional commentary from Dr Matthew Galsky from The Tisch Cancer Institute in New York, New York. CME information and select publications here .

Dr Terence Friedlander from the UCSF Helen Diller Family Comprehensive Cancer Center and Dr Rana R McKay from the UC San Diego Moores Cancer Center summarize the treatment landscape for prostate and urothelial bladder cancer and discuss the implications of clinical findings recently presented at the ESMO Congress 2025. CME information and select publications here .

Dr Emmanuel S Antonarakis and Dr Matthew R Smith share their perspectives on the evolving therapeutic landscape for patients with prostate cancer.  CME information and select publications here .

Dr Jonathan Strosberg from Moffitt Cancer Center in Tampa, Florida, discusses recent updates on available and novel treatment strategies for extrapulmonary neuroendocrine carcinoma.  CME information and select publications here .

Ms Kathleen D Burns from City of Hope Comprehensive Cancer Center in Duarte, California, discusses nursing considerations in the care of patients with prostate cancer.  NCPD information and select publications here .